medwireNews: The cardiac mitotrope ninerafaxstat is well tolerated by patients with nonobstructive hypertrophic cardiomyopathy (nHCM), with early signs of improvements in exercise capacity and health status, a phase 2 trial suggests.
29-04-2024 | Cardiomyopathy | Editor's Choice | News